Global Myasthenia Gravis Drugs Market 2017-2021

Global myasthenia gravis drugs market forecast

Extensive research carried out by the market research analysts at Technavio has shown that the global myasthenia gravis drugs market will witness impressive growth and post a staggering CAGR of more than 13% over the forecast period. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects.

Global myasthenia gravis drugs market drivers

Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies. For instance, Soliris (eculizumab) is one such drug that is currently in Phase III development stage. The drug acts by restricting the disease cells from affecting the immune system. Soliris (eculizumab) is anticipated to receive approval by the end of 2017 or in early 2018 in the US. Some of the other monoclonal antibodies in the pipeline include Novartis' CFZ-533 and GlaxoSmithKline's Benlysta. With several monoclonal antibody-based drugs in the pipeline, the market for myasthenia gravis drugs will have a positive outlook in the coming years.

Global myasthenia gravis drugs market trends

One of the recent myasthenia gravis drugs market trends gaining traction is the growing number of strategic acquisitions in the anticholinesterase drugs market. Several vendors are looking to expand their product portfolio and market presence by pursuing inorganic growth strategies such as acquisitions. Such growth strategies allow companies to reduce R&D costs and quickly establish a presence in the market, for example, Shire acquired Dyax Corp. for a cash consideration of USD 5.9 billion in June 2016. The acquisition helped in expanding Shire’s portfolio across various therapy areas including myasthenia gravis. Such acquisitions are expected to propel the growth of the myasthenia gravis drugs market in the future.

Myasthenia gravis drugs market forecast: Competitive landscape and key vendors

The global myasthenia gravis drugs market is characterized by key companies like Pfizer, Shire, and Grifols. However, these vendors in the anticholinesterase drugs market face stiff competition from the manufacturers of off-label drugs. The advances in R&D activities and the launch of novel therapies will increase the competition among vendors.

Key vendors in the myasthenia gravis drugs market

• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals

Myasthenia gravis drugs market segmentation by therapy area

• Anticholinesterases
• Immunosuppressants
• Intravenous immune globulins

Based on the myasthenia gravis drugs market overview, the anticholinesterases therapy segment was one of the fastest-growing segments and is anticipated to continue to lead the myasthenia gravis drugs market in the coming years. Anticholinesterases is the most common type of medication used for the treatment of myasthenia gravis owing to its lesser long-term side effects. These drugs act by preventing the breakdown of acetylcholine. Although anticholinesterase drugs do not directly counteract the abnormal immune system attack in myasthenia gravis, they may partially or completely control symptoms in some individuals.

Myasthenia gravis drugs market growth based on geography

• Americas
• APAC
• EMEA

In terms of geography, the Americas was the highest revenue generating region and will continue to dominate the anticholinesterase drugs market over the next four years. The growth of this market in the region is owing to the higher prevalence of the disease in the region. Also, the researchers believe that the prevalence should be higher than the estimated value, as the disease remains underdiagnosed. Therefore, the researchers are extensively conducting research activities to understand the disease etiology better. Moreover, several pipeline drugs are expected to receive the US FDA approval by the end of 2017, which is also expected to drive this market’s growth in the Americas.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global myasthenia gravis drugs market?
• What are the key market trends impacting the growth of the global myasthenia gravis drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global myasthenia gravis drugs market?
• What are the market opportunities and threats faced by the vendors in the global myasthenia gravis drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global myasthenia gravis drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Immunoglobulin Products Market 2016-2020
• Global Musculoskeletal Disorders Therapeutics Market 2016-2020
• Global Neurological Biomarkers Market 2016-2020
• Global Foot Drop Implants Market 2016-2020